Trial of Liposomal Versus Plain Bupivacaine in Minimally Invasive General Surgery Procedures

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

January 6, 2020

Study Completion Date

January 6, 2020

Conditions
Pain, Postoperative
Interventions
DRUG

liposomal bupivicaine

"1. The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~2. The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~3. Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~4. Route of drug administration; Surgical site infiltration"

Trial Locations (1)

92134

Naval Medical Center San Diego, San Diego

All Listed Sponsors
lead

United States Naval Medical Center, San Diego

FED

NCT02875288 - Trial of Liposomal Versus Plain Bupivacaine in Minimally Invasive General Surgery Procedures | Biotech Hunter | Biotech Hunter